Exploring parental perspectives: Maternal RSV vaccination versus infant RSV monoclonal antibody.
Hum Vaccin Immunother
; 20(1): 2341505, 2024 Dec 31.
Article
in En
| MEDLINE
| ID: mdl-38723786
ABSTRACT
Respiratory Syncytial Virus poses a significant global public health threat, particularly affecting infants aged less than one year of age. Recently, two forms of passive immunization against infant RSV have been developed and brought to market; nirsevimab a long-acting monoclonal antibody (mAb) and RSV-PreF, a maternal RSV vaccine. The acceptability and uptake of these products will play a pivotal role in determining the success of any national immunization strategy aimed at safeguarding infants from RSV. It is crucial at this time to reflect on the factors that influence parental decisions surrounding immunization to facilitate more informed discussions, enhance healthcare communication, and contribute to the design of effective RSV prevention strategies that resonate with the concerns and aspirations of parents worldwide.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Respiratory Syncytial Virus Vaccines
/
Antibodies, Monoclonal
Limits:
Female
/
Humans
/
Infant
/
Newborn
/
Pregnancy
Language:
En
Journal:
Hum Vaccin Immunother
Year:
2024
Document type:
Article